This article does not advertise a prescription-only medicine or imply that a named treatment is available from the clinic. Treatment decisions require an individual medical consultation.
How does retatrutide work?
Retatrutide is designed to activate GIP, GLP-1 and glucagon receptors.
The combination is being studied for effects on appetite, metabolism, glucose regulation and body weight. Potential benefit must be considered alongside adverse effects and longer-term safety evidence.
What has research shown?
A peer-reviewed phase 2 randomised trial reported substantial average weight reduction over 48 weeks in adults with obesity, with gastrointestinal adverse effects occurring most often during dose escalation.
More recent phase 3 results have also been announced, but some remain company-reported or relate to specific populations. Average research outcomes do not predict an individual result.
Can retatrutide be prescribed in the UK?
No UK marketing authorisation was identified in the source review completed on 12 June 2026.
It must not be promoted as available care. Products sold online under its name may be unlicensed, counterfeit or unlawfully supplied.
Frequently asked questions
No. Regulators separately assess quality, safety and efficacy before granting a marketing authorisation.
Products marketed online should not be assumed genuine, safe or lawful. An investigational medicine should be accessed only within properly authorised research.
References
- New England Journal of Medicine. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. 10 August 2023. Peer-reviewed phase 2 randomised controlled trial. DOI: 10.1056/NEJMoa2301972. Accessed 12 June 2026.
- Medicines and Healthcare products Regulatory Agency. GLP-1 receptor agonists: reminder of potential side effects and misuse. 24 October 2024. UK drug-safety communication. Accessed 12 June 2026.